Valion Bio VBIO
NASDAQ VBIO
$0.93 -0.02 (-2.37%)
As of: Oct 23, 2026 · 1:33 PM EDT

Valion Bio (VBIO) Amortization of Deferred Charges (2021)

Updated

Analysis

Valion Bio (VBIO) Amortization of Deferred Charges (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,134.76 Bn 1,103.34 Bn 19.71 Bn
2 Johnson & Johnson 634.69 Bn 554.55 Bn 17.30 Bn
3 AbbVie 506.51 Bn 479.62 Bn 12.70 Bn
4 Merck 357.95 Bn 312.33 Bn 12.21 Bn
5 Novartis Ag 293.14 Bn 257.13 Bn 11.24 Bn
6 Astrazeneca 265.38 Bn 239.06 Bn 12.86 Bn
7 Amgen 238.37 Bn 193.77 Bn 7.24 Bn
8 Gilead Sciences 195.16 Bn 169.36 Bn 6.22 Bn
9 Pfizer 170.88 Bn 117.53 Bn 10.94 Bn
10 Valion Bio 126,195.68 -19.31 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 134,000.00
Sep 30, 2021 1.14 Mn
Jun 30, 2021 208,000.00
Mar 31, 2021 261,000.00
API Access

Valion Bio Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=VBIO&period=max&api_key=YOUR_API_KEY